Class 2 Recall - Lorazepam 2mg/ml Injection, Lorazepam 4mg/ml Injection (unlicensed medicines)

Hikma Pharmaceuticals USA Inc are recalling the above batches due to an out of specification result with related substances during testing for retain samples. This unlicensed medicine has been imported into the U.K. to meet the special need of individual patients.

MHRA drug alert date: 30 August 2022

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-hikma-pharmaceuticals-usa-inc-lorazepam-2mg-slash-ml-injection-lorazepam-4mg-slash-ml-injection-unlicensed-medicines?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=7ee36a17-10d8-4ee0-9c10-11b3163d55c3&utm_content=immediately

Alliance do not stock the above products so we will not be accepting Customer returns on this recall.

Further Information

For more information or medical enquiries, please contact pv@hikma.com

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.